NeuroSolis Therapeutics Inc.

NeuroSolis Therapeutics is developing a new treatment for essential tremor, a common movement disorder that affects millions of people and is often inadequately controlled by current medications. The company is generating the data needed to demonstrate the therapy's potential and attract a pharmaceutical partner. NeuroSolis follows a capital-efficient strategy focused on creating value through early development and strategic licensing opportunities